Navigation Links
Language Assistance Lacking at Resurrection Hospitals
Date:11/12/2007

e assistance services include providing trained medical translators and interpreters and providing consent forms and discharge instructions in commonly encountered languages.

Resurrection hospitals treat more Latino patients than any other Chicago health care network, yet employees report only two of RHC's eight hospitals employ professional interpreters. Among other area hospitals that treat high numbers of Latino inpatients, the average percent of revenue spent on language assistance services is five times higher than that at Resurrection.

Leticia Gonzales sought care for severe stomach pain at RHC's St. Mary of Nazareth Hospital. Because of the language barrier the medical personnel were never able to effectively diagnose her condition. After months of suffering she was finally brought to another area hospital where she was diagnosed with a severe gallbladder infection that had spread to the kidneys. She underwent an operation and spent 15 days hospitalized in critical condition.

"Resurrection Health Care has more resources than other community hospitals but is doing far less in assuring that patients can get appropriate treatment no matter what language barriers may exist," said AFSCME Council 31 Executive Director, Henry Bayer.

Rev. Larry Dowling, pastor of St. Agatha Catholic Church, also joined in calling for Resurrection to reform its policy.

"We should demand more of any hospital, but we should expect more from a hospital system with a spiritual mission," Father Dowling said. "Beyond the obligation Resurrection has to the public health, they have an obligation to be a beacon of quality health care, administered clearly and understandably, no matter what language you speak."

Idida Perez, Executive Director of West Town Leadership United, summarized the door-to-door survey on barriers to health care access that was conducted over the summer.

"We asked residents who were not fluent in English if they had experie
'/>"/>

SOURCE HEART/AFSCME
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Insight into the struggles of children with language impairments
2. Babies raised in bilingual homes learn new words differently than infants learning one language
3. Toy Blocks Might Boost Toddlers Language Skills
4. GetWellNetwork Expands Foreign Language Support for the PatientLife System
5. Hospitals Say New Cordless Phone Helps Communication With Patients Who Speak Diverse Languages
6. JGIM: studies show importance of language services on disparities, quality of care
7. Studies Show Importance of Language Services on Reducing Disparities, Increasing Quality of Patient Care
8. USAID Provides Additional Wildfire Assistance to Greece
9. PA Department of Public Welfare Begins Outreach to Medical Assistance Consumers Following Burglary at State Office Building
10. HHS Provides Over $131 Million In Energy Assistance
11. Free Prescription Drug Program Uses Internet to Deliver Cards - Offers Assistance to Uninsured
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 2ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 3ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6When palm trees gave way to spruce trees 8890 1When palm trees gave way to spruce trees 8890 2House Subcommittee Markup Leaves Global Fund to Fight AIDS TB and Malaria in Crisis 49310 1House Subcommittee Markup Leaves Global Fund to Fight AIDS TB and Malaria in Crisis 49310 2Mayo Clinic Plans Facility at Mall of America 49306 1Mayo Clinic Plans Facility at Mall of America 49306 2Mayo Clinic Plans Facility at Mall of America 49306 3